Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Myocardial Infarction With PFO: Distinguishing SCAD From Coronary Embolism.

JACC. Case reports·2026

Same author

Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation.

JAMA network open·2025

Same author

Catheter-Directed Aspiration for Right Atrial and Right Ventricular Masses: Trends in Use Over the Years and Comparison Between Percutaneous and Surgical Thrombectomy for Clot in Transit.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025

Same author

Comparison of outcomes of Impella-assisted high-risk percutaneous coronary intervention in patients with and without prior coronary artery bypass graft.

Coronary artery disease·2024

Same author

Yearly Trends and In-Hospital Outcomes of Patients Undergoing Transcatheter Mitral Valve-In-Valve Replacement in Prosthetic Valve Dysfunction.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2024

Same author

Late-onset left atrial appendage occlusion device-related thrombus attributed to mitral bioprosthetic stenosis: a case report.

European heart journal. Case reports·2024

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Mechanical versus pharmacologic support for cardiogenic shock.

Gaurav Dhar¹, Neeraj Jolly

¹Department of Medicine, The University of Chicago Medical Center, Chicago, Illinois 60637, USA.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions

|January 6, 2010

Summary

Dynamic left ventricular outflow tract obstruction can cause cardiogenic shock post-myocardial infarction. Mechanical circulatory support with an Impella pump, alongside discontinuing inotropic agents and balloon pumps, stabilized hemodynamics for successful revascularization.

More Related Videos

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Area of Science:

Cardiology
Cardiovascular Surgery
Critical Care Medicine

Background:

Dynamic left ventricular outflow tract (LVOT) obstruction is a rare complication following acute myocardial infarction (MI).
Cardiogenic shock can arise from this obstruction, leading to hemodynamic instability.
Traditional treatments like inotropic support and intra-aortic balloon pumps (IABP) may exacerbate LVOT obstruction.

Observation:

A case of a patient presenting with cardiogenic shock post-MI was observed.
The patient's hemodynamics worsened with standard inotropic support and IABP.
This clinical course suggested dynamic LVOT obstruction as the underlying mechanism.

Findings:

Mechanical circulatory support with the Impella 2.5 heart pump was initiated.
Discontinuation of inotropic agents and IABP was performed concurrently.
Hemodynamic stabilization was achieved following these interventions.

Implications:

Mechanical circulatory support can be a crucial intervention in managing cardiogenic shock due to dynamic LVOT obstruction.
Careful consideration of therapeutic interventions is necessary, as some may worsen the condition.
This case highlights a successful strategy for managing a rare but severe post-MI complication, enabling subsequent revascularization.